Safety and Efficacy of Adalimumab in Patients With Moderate to Severely Active Psoriatic Arthritis

Abbott

Status and phase: Completed; Phase 3

Conditions: Psoriatic Arthritis

Treatments: Biological: Human anti-TNF monoclonal antibody/adalimumab

Study type: Interventional

Funder types: Industry

Identifiers

NCT00195689

M02-537

Details and patient eligibility

About

The purpose of the study is to assess the long-term safety and clinical efficacy of adalimumab in treatment of moderate to severely active psoriatic arthritis

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subject completed study M02-518 or M02-570

Exclusion criteria

• Subject prematurely discontinued study M02-518 or M02-570

  • Female subject who is pregnant or breast-feeding or considering becoming pregnant
  • Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)